Results 1 to 10 of about 56,186 (320)

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss [PDF]

Frontiers in Oncology, 2023
PurposeTo establish a high-risk prediction model for aromatase inhibitor-associated bone loss (AIBL) in patients with hormone receptor-positive breast cancer.MethodsThe study included breast cancer patients who received aromatase inhibitor (AI) treatment.
Meiling Chu, Yue Zhou, Yulian Yin, Lan Jin, Hongfeng Chen, Tian Meng, Binjun He, Jingjing Wu, Meina Ye   +8 more
doaj   +2 more sources

Aromatase Inhibitors [PDF]

Annals of the New York Academy of Sciences, 2006
Abstract:  Aromatase is the enzyme synthesizing estrogens from androgens. In estrogen‐dependent breast tumors, estrogens induce the expression of growth factors responsible for cancer cell proliferation. In situ estrogen synthesis by aromatase “is thought to play a key role in the promotion of breast cancer growth.
Yanyan, Hong, Shiuan, Chen
  +5 more sources

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [PDF]

, 2015
BACKGROUND: The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.METHODS: We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor ...
, Clarke, Michael
core   +6 more sources

Tissue steroid levels in response to reduced testicular estrogen synthesis in the male pig, Sus scrofa. [PDF]

PLoS ONE, 2019
Production of steroid hormones is complex and dependent upon steroidogenic enzymes, cofactors, receptors, and transporters expressed within a tissue.
Heidi Kucera, Birgit Puschner, Alan Conley, Trish Berger   +3 more
doaj   +2 more sources

Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome [PDF]

Frontiers in Endocrinology
IntroductionAromatase excess syndrome (AEXS) is a rare, autosomal dominant disorder, characterized by enhanced aromatization of androgens and estrogen excess.
Eleni Z. Giannopoulou, Eleni Z. Giannopoulou, Stephanie Brandt, Stephanie Brandt, Stephanie Brandt, Stefanie Zorn, Stefanie Zorn, Stefanie Zorn, Christian Denzer, Christian Denzer, Julia von Schnurbein, Julia von Schnurbein, Maki Fukami, Alexander Kaiser, Martin Schmidt, Martin Wabitsch, Martin Wabitsch, Martin Wabitsch   +17 more
doaj   +2 more sources

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Breast, 2021
Background: The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials.
Phillip S. Blanchette, Melody Lam, Britney Le, Lucie Richard, Salimah Z. Shariff, Alexandra M. Ouédraogo, Kathleen I. Pritchard, Jacques Raphael, Ted Vandenberg, Ricardo Fernandes, Danielle N. Desautels, Kelvin K.W. Chan, Craig C. Earle   +12 more
doaj   +1 more source

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition

Communications Biology, 2023
Endocrine resistance is a major challenge for breast cancer therapy. To identify the genes pivotal for endocrine-resistance progression, we screened five datasets and found 7 commonly dysregulated genes in endocrine-resistant breast cancer cells. Here we
Jing Zhou, Mengdi Zhu, Qi Wang, Yiyuan Deng, Nianqiu Liu, Yujie Liu, Qiang Liu   +6 more
doaj   +1 more source

The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2022
Treatment of patients with castration-resistant prostate cancer (CRPC) remains a major clinical challenge. We previously showed that estrogenic effects contribute to CRPC progression and are primarily caused by the increased endogenous estradiol produced
Qimei Lin, Jiasong Cao, Jiasong Cao, Xiaoling Du, Kuo Yang, Yongmei Shen, Yongmei Shen, Weishu Wang, Helmut Klocker, Jiandang Shi, Jiandang Shi, Ju Zhang   +11 more
doaj   +1 more source

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

Frontiers in Endocrinology, 2021
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs are ...
Tara Hyder, Christopher C. Marino, Sasha Ahmad, Azadeh Nasrazadani, Adam M. Brufsky   +4 more
doaj   +1 more source

Aromatase, aromatase inhibitors, and breast cancer [PDF]

The Journal of Steroid Biochemistry and Molecular Biology, 2011
Estrogens are known to be important in the growth of breast cancers in both pre and postmenopausal women. As the number of breast cancer patients increases with age, the majority of breast cancer patients are postmenopausal women. Although estrogens are no longer made in the ovaries after menopause, peripheral tissues produce sufficient concentrations ...
Saranya, Chumsri, Timothy, Howes, Ting, Bao, Gauri, Sabnis, Angela, Brodie   +4 more
openaire   +2 more sources